What question did this study set out to answer?

This trial aims to evaluate the efficacy and safety of surufatinib combined with different chemotherapy regimens for treating metastatic colorectal cancer.

July 11, 2026Annals of MedicineOpen Access

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer

View Full Paper

Ask AI

Bookmark

Authors

LSLiyu SuFujian Medical University PLPeicheng LinNanjing University of Science and Technology YYY. YinFujian Medical University

Discussion

Member takes

Implication

Randomized trial compares objective response rates in metastatic colorectal cancer, suggesting further studies are needed.

Key Points

This trial aims to evaluate the efficacy and safety of surufatinib combined with different chemotherapy regimens for treating metastatic colorectal cancer.
Multicentre, open-label, randomized phase-II trial with Simon's minimax two-stage design.
Patients with mCRC progressing after first-line doublet chemotherapy were randomized 1:1 to receive surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy.
Primary endpoint was objective response rate (ORR).
In the doublet cohort, ORR was 35.7% (95% CI: 18.6-55.9) with median PFS of 5.4 months and median OS of 19.0 months.
In the triplet cohort, ORR was 39.3% (95% CI: 21.5-59.4) with median PFS of 5.8 months and median OS of 10.9 months.
Grade ≥3 treatment-emergent adverse events were more frequent in the triplet cohort (71.4%) than the doublet cohort (57.1%).

Cite This Study

Su et al. (2026) studied this question.

synapsesocial.com/papers/6a51e329c18d7f28ca50169d https://doi.org/10.1080/07853890.2026.2698360

View Full Paper

Ask AI

Bookmark

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider